HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ILF3
interleukin enhancer binding factor 3
Chromosome 19 · 19p13.2
NCBI Gene: 3609Ensembl: ENSG00000129351.19HGNC: HGNC:6038UniProt: Q12906
454PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTranscription Factor
RESEARCH IMPACT
Highly StudiedTrending
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
membraneDNA bindingRNA bindingdouble-stranded RNA bindingneurodegenerative diseaseosteoarthritisParkinson diseaseAlzheimer disease
✦AI Summary

ILF3 (interleukin enhancer binding factor 3) is a multifunctional RNA-binding protein with diverse roles in cellular regulation and disease pathogenesis. Primary Function: ILF3 functions as an RNA-binding protein involved in mRNA stability and translation regulation 1. It also serves as a lysosomal adaptor protein that tethers GATOR complexes to lysosomes, controlling mTORC1-dependent amino acid sensing 2. Mechanism: ILF3 recognizes m6A-modified RNA sequences and stabilizes target mRNA transcripts including ILF3 itself and SGOC pathway genes 13. It regulates cereblon expression through modulation of CRBN mRNA alternative splicing 4. Disease Relevance: ILF3 is implicated in multiple pathologies—macrophage ILF3 promotes abdominal aortic aneurysm through inflammatory imbalance via NF-κB and Keap1-Nrf2 pathway dysregulation 5. In cancer, elevated ILF3 drives multiple myeloma progression through AKT3 upregulation 1, colorectal cancer growth via SGOC pathway activation 3, and hepatocellular carcinoma resistance to sorafenib through mitochondrial biogenesis 6. ILF3 suppression enables gastric cancer ferroptosis and immunotherapy sensitization 7. Conversely, ILF3 protects against ZIKV infection by enhancing antiviral RNAi pathways 8. Clinical Significance: ILF3 represents a promising therapeutic target across multiple malignancies and inflammatory diseases, with potential for combination therapies.

Sources cited
1
Macrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance through NF-κB and Keap1-Nrf2 pathway dysregulation
PMID: 39179537
2
ILF3 regulates cereblon expression via modulation of CRBN mRNA alternative splicing and affects response to cereblon E3 ligase modulators
PMID: 33197925
3
ILF3 mRNA is m6A-modified and stabilized by HNRNPA2B1, driving multiple myeloma progression through AKT3 expression
PMID: 33794982
4
Simvastatin inhibits ILF3 expression to induce ferroptosis in gastric cancer cells and enhance CD8+ T cell-mediated antitumor immunity
PMID: 40140647
5
Lefamulin targets ILF3 to overcome sorafenib resistance in hepatocellular carcinoma by impairing mitochondrial biogenesis through MRPL12 transcription
PMID: 38874478
6
ILF3 tethers GATOR complexes to lysosomes to control mTORC1-dependent amino acid sensing and autophagy regulation
PMID: 37037994
7
ILF3 is overexpressed in colorectal cancer and regulates serine-glycine-one-carbon pathway genes; ERK-mediated phosphorylation protects ILF3 from SPOP-mediated degradation
PMID: 31772275
8
ILF3 and DHX9 enhance antiviral RNAi by promoting DICER processing of ZIKV-derived siRNAs, protecting against ZIKV-induced microcephaly
PMID: 40011444
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.46Moderate
osteoarthritisOpen Targets
0.42Moderate
Parkinson diseaseOpen Targets
0.36Weak
Alzheimer diseaseOpen Targets
0.36Weak
lysosomal storage diseaseOpen Targets
0.36Weak
multiple sclerosisOpen Targets
0.36Weak
Knee painOpen Targets
0.33Weak
osteoarthritis, kneeOpen Targets
0.31Weak
substance-related disorderOpen Targets
0.29Weak
joint diseaseOpen Targets
0.23Weak
ArthropathyOpen Targets
0.22Weak
osteoarthritis, handOpen Targets
0.20Weak
familial hypercholesterolemiaOpen Targets
0.18Weak
medical procedureOpen Targets
0.14Weak
preeclampsiaOpen Targets
0.14Weak
rheumatoid arthritisOpen Targets
0.12Weak
osteoarthritis, hipOpen Targets
0.12Weak
total knee arthroplastyOpen Targets
0.11Weak
colorectal carcinomaOpen Targets
0.11Weak
neoplasmOpen Targets
0.11Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
ELAVL1Protein interaction100%FUSProtein interaction100%HNRNPA1Protein interaction100%HNRNPA2B1Protein interaction100%HNRNPABProtein interaction100%HNRNPCProtein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
53%
Lung
39%
Brain
39%
Heart
30%
Liver
24%
Gene Interaction Network
Click a node to explore
ILF3ELAVL1FUSHNRNPA1HNRNPA2B1HNRNPABHNRNPC
PROTEIN STRUCTURE
Preparing viewer…
PDB7RJQ · 1.72 Å · X-ray
View on RCSB ↗
RankingsWhere ILF3 stands among ~20K protein-coding genes
  • #602of 20,598
    Most Researched454 · top 5%
Genes detectedILF3
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Macrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice.
PMID: 39179537
Nat Commun · 2024
1.00
2
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
PMID: 33197925
Blood · 2021
0.90
3
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA.
PMID: 33794982
J Hematol Oncol · 2021
0.80
4
Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.
PMID: 40140647
Cell Death Dis · 2025
0.70
5
Single-cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism-related mechanisms.
PMID: 39118300
Clin Transl Med · 2024
0.68